The prognostic significance of the insulin-like growth factor-1 ligand and receptor expression in breast cancer tissue

Journal of Surgical Oncology

Volumn 104, Issue 3, 2011, Pages 228-235

  Chong, Kelvin Y M ^a   Subramanian, Ashok ^a   Mokbel, Kefah ^a   Sharma, Anup K ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

adjacent normal breast tissue; disease free survival; IGF 1; prognosis; risk biomarker

Indexed keywords

BETA ACTIN; MESSENGER RNA; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECEPTOR, IGF TYPE 1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE;

EID: 80051551846     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21916     Document Type: Article

References (32)

1. Moschos SJ, Mantzoros CS,: The role of the IGF system in cancer: From basic to clinical studies and clinical applications. Oncology 2002; 63: 317-332. (Pubitemid 36151524)
2. Rubin R, Baserga R,: Insulin-like growth factor-I receptor. Its role in cell proliferation, apoptosis, and tumorigenicity. Lab Invest 1995; 73: 311-331.
3. Dunn SE, Kari FW, French J, et al.: Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. Cancer Res 1997; 57: 4667-4672. (Pubitemid 27468963)
4. Gooch JL, Van Den Berg CL, Yee D,: Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death-Proliferative and anti-apoptotic effects. Breast Cancer Res Treat 1999; 56: 1-10. (Pubitemid 29435810)
5. Reiss K, Wang JY, Romano G, et al.: IGF-I receptor signaling in a prostatic cancer cell line with a PTEN mutation. Oncogene 2000; 19: 2687-2694. (Pubitemid 30326418)
6. Valentinis B, Navarro M, Zanocco-Marani T, et al.: Insulin receptor substrate-1, p70S6K, and cell size in transformation and differentiation of hemopoietic cells. J Biol Chem 2000; 275: 25451-25459.
7. Andre F, Rigot V, Thimonier J, et al.: Integrins and E-cadherin cooperate with IGF-I to induce migration of epithelial colonic cells. Int J Cancer 1999; 83: 497-505. (Pubitemid 29489865)
8. Guerra FK, Eijan AM, Puricelli L, et al.: Varying patterns of expression of insulin-like growth factors I and II and their receptors in murine mammary adenocarcinomas of different metastasizing ability. Int J Cancer 1996; 65: 812-820. (Pubitemid 26126266)
9. Colletti RB, Roberts JD, Devlin JT, et al.: Effect of tamoxifen on plasma insulin-like growth factor I in patients with breast cancer. Cancer Res 1989; 49: 1882-1884. (Pubitemid 19108421)
10. Friedl A, Jordan VC, Pollak M,: Suppression of serum insulin-like growth factor-1 levels in breast cancer patients during adjuvant tamoxifen therapy. Eur J Cancer 1993; 29A: 1368-1372. (Pubitemid 23195373)
11. Pollak MN, Polychronakos C, Richard M,: Insulinlike growth factor I: A potent mitogen for human osteogenic sarcoma. J Natl Cancer Inst 1990; 82: 301-305. (Pubitemid 20097703)
12. Torrisi R, Colleoni M, Veronesi P, et al.: Primary therapy with ECF in combination with a GnRH analog in premenopausal women with hormone receptor-positive T2-T4 breast cancer. Breast 2007; 16: 73-80. (Pubitemid 46172859)
13. Decensi A, Veronesi U, Miceli R, et al.: Relationships between plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3 and second breast cancer risk in a prevention trial of fenretinide. Clin Cancer Res 2003; 9: 4722-4729. (Pubitemid 37323274)
14. Gail MH, Brinton LA, Byar DP, et al.: Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989; 81: 1879-1886. (Pubitemid 20026073)
15. Gail MH, Costantino JP, Bryant J, et al.: Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 1999; 91: 1829-1846.
16. Yarden RI, Wilson MA, Chrysogelos SA,: Estrogen suppression of EGFR expression in breast cancer cells: A possible mechanism to modulate growth. J Cell Biochem 2001; 81: 232-246.
17. Haffner MC, Petridou B, Peyrat JP, et al.: Favorable prognostic value of SOCS2 and IGF-I in breast cancer. BMC Cancer 2007; 7: 136.
18. Shin A, Ren Z, Shu XO, et al.: Expression patterns of insulin-like growth factor 1 (IGF-I) and its receptor in mammary tissues and their associations with breast cancer survival. Breast Cancer Res Treat 2007; 105: 55-561.
19. Toropainen E, Lipponen P, Syrjanen K,: Expression of insulin-like growth factor I (IGF-I) in female breast cancer as related to established prognostic factors and long-term prognosis. Eur J Cancer 1995; 31A: 1443-1448.
20. Jiang WG, Watkins G, Lane J, et al.: Prognostic value of rho GTPases and rho guanine nucleotide dissociation inhibitors in human breast cancers. Clin Cancer Res 2003; 9: 6432-6440. (Pubitemid 38031830)
21. Pawlowski V, Revillion F, Hebbar M, et al.: Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res 2000; 6: 4217-4225.
22. Foekens JA, Portengen H, van Putten WL, et al.: Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. Cancer Res 1989; 49: 7002-7009. (Pubitemid 20016583)
23. Shimizu C, Hasegawa T, Tani Y, et al.: Expression of insulin-like growth factor 1 receptor in primary breast cancer: Immunohistochemical analysis. Hum Pathol 2004; 35: 1537-1542. (Pubitemid 40017995)
24. Law JH, Habibi G, Hu K, et al.: Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 2008; 68: 10238-10246.
25. Migliaccio I, Wu MF, Gutierrez C, et al.: Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer. Breast Cancer Res Treat 2009.
26. Rocha RL, Hilsenbeck SG, Jackson JG, et al.: Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: Correlation with clinical parameters and disease-free survival. Clin Cancer Res 1997; 3: 103-109. (Pubitemid 27079451)
27. Baserga R, Rubin R,: Cell cycle and growth control. Crit Rev Eukaryot Gene Expr 1993; 3: 47-61. (Pubitemid 23088857)
28. Valentinis B, Romano G, Peruzzi F, et al.: Growth and differentiation signals by the insulin-like growth factor 1 receptor in hemopoietic cells are mediated through different pathways. J Biol Chem 1999; 274: 12423-12430.
29. Blamey RW, Hornmark-Stenstam B, Ball G, et al.: ONCOPOOL-A European database for 16,944 cases of breast cancer. Eur J Cancer 2010; 46: 56-71.
30. Goldhirsch A, Glick JH, Gelber RD, et al.: Meeting highlights: International expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005; 16: 1569-1583. (Pubitemid 41511089)
31. Allred DC, Harvey JM, Berardo M, et al.: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998; 11: 155-168. (Pubitemid 28144151)
32. Verschraegen C, Vinh-Hung V, Cserni G, et al.: Modeling the effect of tumor size in early breast cancer. Ann Surg 2005; 241: 309-318.